Eli Lilly lands in southeast Wisconsin the week of Foundayo's launch push and Lebanon plant expansion

Eli Lilly flew from Indianapolis International Airport to a destination in southeast Wisconsin on Monday, May 18, 2026, aboard a Gulfstream G500 (tail N307EL). The 43-minute hop landed the company at a site just northeast of Chicago, a region where Eli Lilly is making its deepest manufacturing bet in U.S. history.

The same week, Eli Lilly is pushing its new oral GLP-1 drug Foundayo, with more than 20,000 prescriptions written in its first few weeks, CEO Dave Ricks told CNBC. The trip also follows the May 6 opening of the company's first dedicated genetic medicine manufacturing facility in Lebanon, Indiana, where Eli Lilly announced an additional $4.5 billion investment, per the company's press release. The Lebanon campus is the cornerstone of a $21 billion domestic manufacturing buildout that will produce Foundayo, Mounjaro and Zepbound.

The visit mirrors a pattern of Eli Lilly executives traveling to key production and policy sites in the region; recent flights show the G500 shuttling between Indianapolis, New York, Boston, Seattle, and Toronto around earnings, the Semafor World Economy summit, and regulatory events. This trip lands at the Wisconsin site as Eli Lilly scales production to meet what Ricks calls "organic demand" for its weight-loss pill franchise.